<DOC>
	<DOCNO>NCT02214706</DOCNO>
	<brief_summary>The purpose study improve therapeutic outcome laser therapy port wine stain use combination treatment pulse dye laser ( PDL ) , erbium yag laser topical sirolimus .</brief_summary>
	<brief_title>Treatment Port Wine Stains Using Pulsed Dye Laser , Erbium Yag Laser Topical Sirolimus</brief_title>
	<detailed_description>In first treatment period patient receive total five treatment two week interval . Every patient receive follow four treatment ( utilize template separate square 1cm2 ) : 1 ) PDL treatment follow topical sirolimus application Er : Yag laser ablation stratum corneum compare 2 ) PDL treatment follow topical sirolimus application without Er : Yag laser ablation stratum corneum , 3 ) PDL treatment 4 ) sirolimus application . After six month follow-up period , second treatment period , patient receive additional five treatment adjacent cosmetic unit treat part PWS , employ successful four treatment modality evaluate first treatment period .</detailed_description>
	<mesh_term>Port-Wine Stain</mesh_term>
	<mesh_term>Hemangioma , Capillary</mesh_term>
	<mesh_term>Vascular Malformations</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Subject provide informed consent ; Subject â‰¥ 18 year age time screen ; Subject extrafacial homogenous Port Wine Stain ( PWS ) ; The PWS large enough size fit one templates Subject receive laser treatment PWS last 3 month ( treatment area ) ; The PWS minimal erythema grade score 3 ( 4 point scale ) opinion investigator ; Screening blood safety value within normal parameter regard clinically significant opinion investigator . PWS nodular/hypertrophic component treatment area ; PWS cosmetically unacceptable location opinion investigator ; For woman : pregnant breast feeding treatment period ; Women childbearing potential , unless use adequate contraceptive measure Subject know immune deficiency , immune compromise Known allergy sirolimus constituent study medication ; Incapacitated subject ; Any medical psychiatric condition , investigator 's opinion , would preclude participant adhere protocol complete study per protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>